Ads
related to: nanobody therapy for prostate cancer- Educational Brochures
Get Resources Now For
APC Treatment
- Safety & Efficacy Video
Watch A Video To Learn
More About This Treatment Option.
- Coverage for Rx Treatment
Learn About Coverage
In Your Area
- Access Patient Resources
Download Dosing Card &
Support Program Brochure
- Patient Support Program
Support to Help Your Patients
Get Started and Stay on Track
- Find Patient Support
Discover Available Options
To Support Your Patients
- Educational Brochures
Search results
Results From The WOW.Com Content Network
Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). [5] [6] Lutetium (177 Lu) vipivotide tetraxetan is a targeted radioligand therapy. [6] [8]
Radiation therapy is commonly used in prostate cancer treatment. It may be used instead of surgery or after surgery in early-stage prostate cancer (adjuvant radiotherapy). Radiation treatments also can be combined with hormonal therapy for intermediate risk disease, when surgery or radiation therapy alone is less likely to cure the cancer.
A single-domain antibody is a peptide chain of about 110 amino acids long, comprising one variable domain (V H) of a heavy-chain antibody, or of a common IgG.These peptides have similar affinity to antigens as whole antibodies, but are more heat-resistant and stable towards detergents and high concentrations of urea.
Siltuximab was also tested in the phase I/II study for therapy of patients with metastatic castration-associated prostate cancer in combination with docetaxel and in renal cell carcinoma; phase II trials in ovarian cancer resulted in 39% of patients showed disease stabilization via IL-6-regulated downregulation of CCL2, CXCL12 and VEGF.
LDR prostate brachytherapy (seed or polymer source implantation) is a very effective treatment for low to high risk localized cancer, with patients rapidly returning to normal activities. [15] Although patients may experience urinary problems for the first six months or so after their implant, these usually settle down and lasting problems are ...
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
Ad
related to: nanobody therapy for prostate cancer